Protective Effects of Intranasal Losartan in the APP/PS1 Transgenic Mouse Model of Alzheimer Disease

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Rejuvenation Research

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/rej.2009.0944PMID 20370487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors

  2009cited by this paper
• Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity

  2009cited by this paper
• Identification of Antihypertensive Drugs Which Inhibit Amyloid-β Protein Oligomerization

  2009cited by this paper
• Intranasal delivery of cells to the brain.

  2009cited by this paper
• Intranasal Deferoxamine Provides Increased Brain Exposure and Significant Protection in Rat Ischemic Stroke

  2009cited by this paper
• The inflammatory response in the MPTP model of Parkinson’s disease is mediated by brain angiotensin: relevance to progression of the disease

  2009influential reference
• Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats.

  2008cited by this paper
• Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease

  2008cited by this paper
• Angiotensin-Converting Enzyme Converts Amyloid β-Protein 1–42 (Aβ1–42) to Aβ1–40, and Its Inhibition Enhances Brain Aβ Deposition

  2007cited by this paper
• Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes

  2007cited by this paper
• Arterial Blood Pressure and Renal Sodium Excretion in Dopamine D3 Receptor Knockout Mice

  2007cited by this paper
• Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice.

  2007cited by this paper
• Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly.

  2007cited by this paper
• Angiotensin Receptor Type 1 Blockade in Astroglia Decreases Hypoxia-Induced Cell Damage and TNF Alpha Release

  2007cited by this paper
• Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition.

  2007cited by this paper
• Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease.

  2007cited by this paper
• Angiotensin II: multitasking in the brain

  2006cited by this paper
• The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain.

  2006cited by this paper
• Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease

  2005cited by this paper
• Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling.

  2005cited by this paper
• Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration.

  2004cited by this paper
• Central Nervous System Blockade by Peripheral Administration of AT1 Receptor Blockers

  2003cited by this paper
• Combined action of the ACE D- and the G-protein β3 T-allele in major depression: a possible link to cardiovascular disease?

  2002cited by this paper
• Potential for antihypertensive treatment with an AT1-receptor blocker to reduce dementia in the elderly

  2002cited by this paper
• Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia.

  2001cited by this paper
• Angiotensin converting enzyme inhibitors as potential cognitive enhancing agents.

  1994cited by this paper
• Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro.

  1989cited by this paper
• Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey

  1986cited by this paper

• Angiotensin II–Stimulating Antihypertensive Medications and Dementia-Related Neuropathology

  2026cites this paper
• Unraveling the role of brain renin angiotensin system in vascular dementia: mechanisms and therapeutic perspectives

  2025cites this paper
• The application of telmisartan in central nervous system disorders

  2025cites this paper
• Investigation of the Effects of Losartan and Captopril on Rotenone-Induced Inflammation via TLR4/NLRP3 Pathway: An Integrative In Vitro and In Silico Study.

  2025cites this paper
• Current updates on latest basic research of scientific relevance in hypertensive dementia

  2025influential citation
• Repositioning of Angiotensin II Receptor Blockers for Alzheimer’s Disease: An In-Silico Study

  2025cites this paper
• Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies.

  2025cites this paper
• Advantages and challenges of using arterial spin labelling MRI to monitor cerebral blood flow in multi-centre clinical trials of neurodegenerative disease: Experience from the RADAR study

  2025cites this paper
• Effects of Telmisartan on Intraocular Pressure, Blood Pressure, and Ocular Perfusion Pressure in Normal and Glaucomatous Cats

  2024cites this paper
• Revolutionising Neurological Therapeutics: Investigating Drug Repurposing Strategies.

  2024cites this paper
• Deciphering mechanisms of action of ACE inhibitors in neurodegeneration using Drosophila models of Alzheimer’s disease

  2023cites this paper
• Therapeutic Implications of Renin–Angiotensin System Modulators in Alzheimer’s Dementia

  2023cites this paper
• Decoding Angiotensin Receptors: TOMAHAQ‐Based Detection and Quantification of Angiotensin Type‐1 and Type‐2 Receptors

  2023cites this paper
• Renin Angiotensin System as a Potential Treatment Target for Traumatic Brain Injury: A Systematic Review and Meta-Analysis

  2022cites this paper
• Targeting Brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: past, present and future.

  2022cites this paper
• Angiotensin receptor blocker use is associated with upregulation of the memory-protective angiotensin type 4 receptor (AT_4R) in the postmortem brains of individuals without cognitive impairment

  2022cites this paper
• Impact of the Renin-Angiotensin System on the Pathogeny and Pharmacotherapeutics of Neurodegenerative Diseases

  2022cites this paper
• Effects of Combined Anti-Hypertensive and Statin Treatment on Memory, Fear Extinction, Adult Neurogenesis, and Angiogenesis in Adult and Middle-Aged Mice

  2021cites this paper
• The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status

  2021cites this paper
• Systemic Candesartan Treatment Modulates Behavior, Synaptic Protein Levels, and Neuroinflammation in Female Mice That Express Human APOE4

  2021cites this paper
• Chronic Renin-Angiotensin System Activation Induced Neuroinflammation: Common Mechanisms Underlying Hypertension and Dementia?

  2021cites this paper
• Higher Angiotensin II type 1 receptor (AT1R) levels and activity in the post-mortem brains of older persons with Alzheimer's disease.

  2021cites this paper
• Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It

  2021cites this paper
• Synthesis and Characterization of Nanoporous Carbon Carriers for Losartan Potassium Delivery

  2021cites this paper
• Losartan to slow the progression of mild-to-moderate Alzheimer’s disease through angiotensin targeting: the RADAR RCT

  2021cites this paper
• Angiotensin II Disrupts Neurovascular Coupling by Potentiating Calcium Increases in Astrocytic Endfeet

  2021cites this paper
• Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial

  2021cites this paper
• Effects of Antihypertensive Drugs on Cognitive Function in Elderly Patients with Hypertension: A Review

  2021cites this paper
• Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders

  2021cites this paper
• Losartan Improves Memory, Neurogenesis and Cell Motility in Transgenic Alzheimer’s Mice

  2021cites this paper
• Drug repositioning and repurposing for Alzheimer disease

  2020cites this paper
• Brain Renin–Angiotensin System at the Intersect of Physical and Cognitive Frailty

  2020cites this paper
• RP1, a RAGE antagonist peptide, can improve memory impairment and reduce Aβ plaque load in the APP/PS1 mouse model of Alzheimer's disease.

  2020cites this paper
• Aβ-accelerated neurodegeneration caused by Alzheimer’s-associated ACE variant R1279Q is rescued by angiotensin system inhibition in mice

  2020cites this paper
• Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers.

  2020cites this paper
• Drug Repurposing in Neurological Diseases: Opportunities and Challenges

  2020cites this paper
• Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer’s disease

  2020cites this paper
• Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system.

  2020cites this paper
• Mechanisms Involved in Superiority of Angiotensin Receptor Blockade over ACE Inhibition in Attenuating Neuropathic Pain Induced in Rats

  2020cites this paper
• Coronavirus Disease-2019 Conundrum: RAS Blockade and Geriatric-Associated Neuropsychiatric Disorders

  2020cites this paper
• Brain angiotensin II and angiotensin IV receptors as potential Alzheimer’s disease therapeutic targets

  2020cites this paper
• Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing

  2020cites this paper
• A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery

  2020cites this paper
• Repurposing Antihypertensive Drugs for the Management of Alzheimer's Disease.

  2020cites this paper
• ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer’s disease

  2020cites this paper
• Title: Cerebrospinal fluid changes in the renin-angiotensin system in Alzheimer’s disease

  2019cites this paper
• A Comparative Study on the Memory-Enhancing Actions of Oral Renin-Angiotensin System Altering Drugs in Scopolamine-Treated Mice

  2019cites this paper
• Calpastatin Mediates Development of Alzheimer’s Disease in Diabetes

  2019cites this paper
• Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats

  2019cites this paper
• Drug interactions with dementia‐related pathophysiological pathways worsen or prevent dementia

  2019cites this paper
• DEMENTIA: A NEURODEGENERATIVE DISORDER

  2019cites this paper
• Candesartan Neuroprotection in Rat Primary Neurons Negatively Correlates with Aging and Senescence: a Transcriptomic Analysis

  2019cites this paper
• The Relationship Between the Use of Antihypertensive Drugs and the Incidence of Dementia in General Practices in Germany

  2019influential citation
• Telmisartan ameliorates Aβ oligomer-induced inflammation via PPARγ/PTEN pathway in BV2 microglial cells.

  2019cites this paper
• Losartan modulates brain inflammation and improves mood disorders and memory impairment induced by innate immune activation: The role of PPAR-γ activation.

  2019cites this paper
• Therapeutic Intranasal Delivery for Alzheimer’s Disease

  2019cites this paper
• Activation of cyclin D1 affects mitochondrial mass following traumatic brain injury.

  2018cites this paper
• Pleiotropic Benefits of the Angiotensin Receptor Blocker Candesartan in a Mouse Model of Alzheimer Disease

  2018cites this paper
• Role of Post-Transcriptional Control of Calpain by miR-124-3p in the Development of Alzheimer’s Disease

  2018cites this paper
• Old Drugs as New Treatments for Neurodegenerative Diseases

  2018cites this paper
• Candesartan ameliorates brain inflammation associated with Alzheimer's disease

  2018cites this paper
• Telmisartan Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor Blockade or PPARγ Activation

  2018cites this paper
• The Coming of Age of the Angiotensin Hypothesis in Alzheimer’s Disease: Progress Toward Disease Prevention and Treatment?

  2018cites this paper
• Angiotensin II Receptor Blockers Attenuate Lipopolysaccharide-Induced Memory Impairment by Modulation of NF-κB-Mediated BDNF/CREB Expression and Apoptosis in Spontaneously Hypertensive Rats

  2018cites this paper
• Gene Therapy for Cognitive Recovering After Ischemic Stroke

  2018cites this paper
• The Renin-Angiotensin System and the Neurodegenerative Diseases: A Brief Review.

  2017cites this paper
• Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.

  2017cites this paper
• Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain—Its Possible Clinical Applications

  2017cites this paper
• Beneficial effects of Angiotensin II receptor blockers in brain disorders

  2017cites this paper
• Antihypertensive Treatment is associated with MRI-Derived Markers of Neurodegeneration and Impaired Cognition: A Propensity-Weighted Cohort Study

  2017cites this paper
• The Rationale and Design of the Reducing Pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) Trial

  2017cites this paper
• Terapia génica en enfermedades neurodegenerativas y demencia post infarto cerebral: perspectiva de traslación

  2017cites this paper
• Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation

  2017cites this paper
• Emerging treatments for Alzheimer’s disease for non-amyloid and non-tau targets

  2017cites this paper
• Losartan improves cerebrovascular function in a mouse model of Alzheimer's disease with combined overproduction of amyloid-β and transforming growth factor-β1

  2017cites this paper
• Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease

  2017cites this paper
• Crosstalk between angiotensin and the nonamyloidogenic pathway of Alzheimer's amyloid precursor protein

  2017cites this paper
• Protective effect of losartan and ramipril against stress induced insulin resistance and related complications: Anti‐inflammatory mechanisms

  2017cites this paper
• Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington’s Disease

  2017cites this paper
• Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-β (Aβ) Plaque Load and Aβ-Synthesizing and Aβ-Degrading Enzymes in Frontal Cortex

  2016cites this paper
• Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer’s Disease

  2016cites this paper
• Renin-angiotensin system-targeting antihypertensive drugs and risk of vascular cognitive impairment: A meta-analysis.

  2016cites this paper
• Effects of Lactobacillus plantarum TWK10-Fermented Soymilk on Deoxycorticosterone Acetate-Salt-Induced Hypertension and Associated Dementia in Rats

  2016cites this paper
• Neuroendocrine immunomodulation network dysfunction in SAMP8 mice and PrP-hAβPPswe/PS1ΔE9 mice: potential mechanism underlying cognitive impairment

  2016influential citation
• Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology

  2016cites this paper
• Telmisartan Modulates Glial Activation: In Vitro and In Vivo Studies

  2016cites this paper
• Neurovascular and Cognitive failure in Alzheimer’s Disease: Benefits of Cardiovascular Therapy

  2016cites this paper
• LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1ΔE9 transgenic mice

  2016cites this paper
• An integrative genome-wide transcriptome reveals that candesartan is neuroprotective and a candidate therapeutic for Alzheimer’s disease

  2016cites this paper
• Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34

  2016cites this paper
• Neuroinflammation: A Therapeutic Target of Cotinine for the Treatment of Psychiatric Disorders?

  2016cites this paper
• Enalapril Alone or Co-Administered with Losartan Rescues Cerebrovascular Dysfunction, but not Mnemonic Deficits or Amyloidosis in a Mouse Model of Alzheimer's Disease.

  2016cites this paper
• The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer's disease: A meta-analysis.

  2016cites this paper
• Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model

  2016cites this paper
• Renin-angiotensin system blockade use and risks of cognitive decline and dementia: A meta-analysis.

  2016cites this paper
• ANTI-INFLAMMATORY ACTIVITY OF LOSARTAN IN EXPERIMENTALLY-INDUCED RESPIRATORY DISEASE IN RAT MODEL

  2016cites this paper
• Therapeutic Effects of Transplantation of As-MiR-937-Expressing Mesenchymal Stem Cells in Murine Model of Alzheimer's Disease

  2015cites this paper
• Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer's Disease.

  2015cites this paper
• Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia

  2015cites this paper
• Vascular risk factors aggravate the progression of Parkinson's disease: a five-year follow-up study in Chinese patients.

  2015cites this paper